Pharmaceutical companies Bayer (OTC: BAYR.Y), Eli Lilly (NYSE: LLY), and AstraZeneca (NASDAQ: AZN) had big years last year, bucking the rest of the market, and each stock saw share gains over the past year.

All three companies have new drugs that were either recently launched or are likely to get final regulatory approval in 2023. As such, investors should expect to again see share price and revenue gains this year for the trio. Let's find out a bit more about these three pharmaceutical growth stocks.

Bayer's stock is up more than 4.5% over the past year, thanks to strong financials and an even stronger pipeline. The company reported nine-month sales of $41.5 billion, up 17.5% year over year, and a nine-month net income of $3.8 billion, compared to a loss of $172.8 million in the same period a year ago.

Continue reading

Source Fool.com